UNSPSC 51201813: Betazole

This classification denotes a diagnostic reagent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1C065P542O. European Medicines Agency schedules Betazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05805MIG. Betazole generally arises in the molecular formula C5H9N3. The term BETAZOLE is an International Non-Proprietary Name or INN. BETAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule betazole under HS 29331990 and SITC 51571. As of Q4 2014, BETAZOLE remains the US FDA Preferred Term for this commodity. Betazole bears US NLM identifiers UMLS ID C0005321 and NCI Concept Code C65258. SMILES: C1=C(NN=C1)CCN.

UNSPSC 51201813 Betazole, a Commodity code, does not reflect the work state and local governments are actually buying under this classification. The single recent opportunity posted under this code is the Mississippi State Department of Health's sole source procurement notice for Yellow Fever Vaccine from Sanofi Pasteur, Inc., due August 3, 2026. The vaccine procurement is not a pharmaceutical active ingredient but a finished immunological product, which falls outside the scope of betazole as a diagnostic or pharmaceutical intermediate. This mismatch suggests the code carries minimal relevant recent procurement activity, or that the state procurement office applied a misaligned classification to this health department solicitation.

State health departments appear to be the primary issuing bodies for opportunities tagged under this code, though the single recent notice provides insufficient basis to characterize issuing-body patterns or geographic concentration. The Mississippi procurement was posted as a sole source notice with an objection period rather than a competitive bid; if no substantiated objections are received demonstrating alternative sources, the department will proceed to award directly to Sanofi Pasteur without publishing estimated value, quantity, or contract term. Firms currently pursuing state and local opportunities under UNSPSC 51201813 should verify that their product offering aligns with actual buying patterns, as the code's nominal definition and recent solicitation activity diverge significantly.